Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis

References

• Chen S, Ravallion M The developing world is poorer than we thought, but no less successful in the fight against poverty. World Bank Policy Research Working Paper WPS 4703 [Internet]; 2008 [cited 2014 Nov 24]. Available from: http://elibrary.worldbank.org/doi/pdf/10.1596/1813-9450-4703
   Google Scholar
• Von Schirding Y. The world summit on sustainable development: reaffirming the centrality of health. Global Health. 2005;1:8.
   Web of Science ®Google Scholar
• Banerjee A. Who has responsibility for access to essential medical drugs in the developing world? Ethics Econ. 2006;4:1–23.
   Google Scholar
• Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28:692–20.
   PubMed Web of Science ®Google Scholar
• Wiedenmayer K. Access to medicines. Medicine supply: lessons learnt in Tanzania and Mozambique. Berne, Switzerland: Swiss Agency for Development and Cooperation (SDC); 2004.
   Google Scholar
• Moye-Holz D, Van Dijk JP, Reijneveld SA, et al. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country. Global Health. 2017;13:53.
   Web of Science ®Google Scholar
• Vialle-Valentin CE, Serumaga B, Wagner AK, et al. Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries. Health Policy Plan. 2015;30:1044–1052.
   PubMed Web of Science ®Google Scholar
• Kishore SP, Kolappa K, Jarvis JD, et al. Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries. Health Aff (Millwood). 2015;34:1569–1577.
   Web of Science ®Google Scholar
• Zodpey S, Pandey A, Murhekar M, et al. Landscaping capacity-building initiatives in epidemiology in India: bridging the demand-supply gap. WHO South East Asia J Public Health. 2015;4:204–212.
   Google Scholar
• Creese A, Gasman N, Mariko M. The world medicines situation. Geneva: World Health Organization; 2004 [cited 2014 Nov 24].
   Google Scholar
• Ministry of Health and Family Welfare. National health accounts- India. National health counts cell. New Delhi: Government of India; 2009.
   Google Scholar
• Selvaraj S, Aisola M, Mehta A, et al. An independent evaluation of National Pharmaceutical Pricing Policy 2012 and Drug Prices Control Order 2013. Delhi, India: ISID-PHFI Collaborative Research Programme; 2014.
   Google Scholar
• Haley GT, Haley UCV. The effects of patent-law changes on innovation: the case of India’s pharmaceutical industry. Technol Forecast Soc Change. 2012;79:607–619.
   Web of Science ®Google Scholar
• Jung Y, Kwon S. The effects of intellectual property rights on access to medicines and catastrophic expenditure. Int J Health Serv. 2015;45:507–529.
   Web of Science ®Google Scholar
• Velasquez G. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property. Dev World Bioeth. 2014;14:67–74.
   Web of Science ®Google Scholar
• Reinhardt UE. Can efficiency in health care be left to the market? J Health Polit Policy Law. 2001;26:967–992.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Hollis A, Pogge T. The Health Impact Fund: incentives for improving access to medicines. Lancet. 2010;375:166–169.
   PubMed Web of Science ®Google Scholar
• Quick JD. Ensuring access to essential medicines in the developing countries: a framework for action. Clin Pharmacol Ther. 2003;73:279–283.
   PubMed Web of Science ®Google Scholar
• Deaton A. Health, inequality, and economic development. J Econ Lit. 2003;41:113–158.
   Web of Science ®Google Scholar
• Kotwani A. Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all. BMC Health Serv Res. 2013;13:285.
   PubMed Web of Science ®Google Scholar
• Bansal D, Purohit VK. Accessibility and use of essential medicines in health care: current progress and challenges in India. J Pharmacol Pharmacother. 2013;4:13–18.
   Google Scholar
• Reddy KS, Patel V, Jha P, et al. Towards achievement of universal health care in India by 2020: a call to action. Lancet. 2011;377:760–768.
   PubMed Web of Science ®Google Scholar
• Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discovery. 2009;8:959–968.
   PubMed Web of Science ®Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discovery. 2010;9:203–214.
   PubMed Web of Science ®Google Scholar
• The Health Impact Fund. Available from: http://healthimpactfund.org/
   Google Scholar
• Pogge T, Hollis A. The Health Impact Fund: making new medicines accessible to all. New Haven: Incentives for Global Health; 2008.
   Google Scholar
• Hollis A, Pogge T, Singer P, et al. The Health Impact Fund: pay-for-performance. In: Submission to WHO expert group for public health, innovation, and intellectual property. New Haven, USA: Incentives for Global Health; 2009 Apr.
   Google Scholar
• Banerjee A, Pogge T. The Health Impact Fund: how might it work for novel anticoagulants in atrial fibrillation? Global Heart. 2014;9:255–261.
   Google Scholar
• Newman C, Ajay VS, Srinivas R, et al. Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis. J Pharm Policy Pract. 2016;9:16.
   Google Scholar
• Schmeer K. Guidelines for conducting a stakeholder analysis. Washington (DC): Partners for Health Reform; 1999.
   Google Scholar
• Varvasovszky Z, Brugha R. A stakeholder analysis. Health Policy Plan. 2000;15:338–345.
   PubMed Web of Science ®Google Scholar
• Knai C, McKee M, Pudule I. Soft drinks and obesity in Latvia: a stakeholder analysis. Eur J Public Health. 2011;21:295–299.
   Web of Science ®Google Scholar
• Akinci F, Mollahaliloglu S, Gursoz H, et al. Assessment of the Turkish health care system reforms: a stakeholder analysis. Health Policy. 2012;107:21–30.
   Web of Science ®Google Scholar
• Patton MQ. Qualitative research & evaluation methods. 3rd ed. Thousand Oaks (CA): Sage; 2002.
   Google Scholar
• Morse JM. The significance of saturation. Qual Health Res. 1995;5:147–149.
   Web of Science ®Google Scholar
• Corbin J, Strauss A. Basics of qualitative research: grounded theory techniques and procedures. Newbury Park (CA): Sage; 1990.
   Google Scholar
• Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277–1288.
   PubMed Web of Science ®Google Scholar
• Thomas DR A general inductive approach for qualitative data analysis. 2003; [cited 2015 Apr 28]. Available from: http://www.frankumstein.com/PDF/Psychology/Inductive%20Content%20Analysis.pdf
   Google Scholar
• Sandelowski M. The use of quotes in qualitative research. Res Nurs Health. 1994;17:479–482.
   PubMed Web of Science ®Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349–357.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Priority Setting for Health Policy and Systems Research in Access to Medicines in India; 2013 [cited 2015 May 1]. Available from: http://www.who.int/alliance-hpsr/projects/alliancehpsr_indiaatmresummary.pdf.pdf?ua=1
   Google Scholar
• Subramanian SV, Ackerson LK, Subramanyam MA, et al. Health inequalities in India: the axes of stratification. Brown J World Aff. 2008;14:127–139.
   Google Scholar
• Access GBDH, Quality Collaborators. Electronic address cue, Access GBDH, Quality C. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017;390:231–266.
   Web of Science ®Google Scholar
• Danelich IM, Reed BN, Hollis IB, et al. Clinical update on the management of atrial fibrillation. Pharmacother J Hum Pharmacol Drug Ther. 2013;33:422–446.
   Google Scholar
• Prashanth NS, Elias MA, Pati MK, et al. Improving access to medicines for non-communicable diseases in rural India: a mixed methods study protocol using quasi-experimental design. BMC Health Serv Res. 2016;16:421.
   Web of Science ®Google Scholar
• Da Fonseca EM. How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health-industry complex in Brazil. Glob Public Health. 2017;13:489–502.
   Web of Science ®Google Scholar
• Ferrario A, Araja D, Bochenek T, et al. The implementation of managed entry agreements in central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271–1285.
   Web of Science ®Google Scholar
• Mathew P. Generic drugs: review and experiences from South India. J Family Med Prim Care. 2015;4:319–323.
   PubMedGoogle Scholar
• Maniadakis N, Kourlaba G, Shen J, et al. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. BMC Health Serv Res. 2017;17:371.
   Web of Science ®Google Scholar